Buildingpharmabrands. Drug Development Life Cycle. Sun Pharma beats GlaxoSmithKline to enter top 3. After eight months of neck and neck contest, Sun Pharma knocked out GlaxoSmithKline (GSK) to wrest get the tag of third-largest domestic drugmaker by market share in the R68,000-crore domestic pharma market.
Sun grabbed a 4.69% market share for the period of 12 months ended September to beat GSK, which commanded a share of 4.67%, according to pharma research firm Aiocd Awacs. The difference in revenues remains wafer-thin at R15 crore. Sun logged R3,201 crore of sales in the domestic market in the 12 months period ended September compared with GSK’s R3,185 crore of sales for a similar period. But two important indicators — the growth rates, revenue minus bonus to trade channels — foretells how Sun’s lead may grow from here. Firstly, Sun grew at a faster pace of over 24% last year while GSK posted a growth rate of 19.8%. Pharmaceutical Marketing - Segmentation.
Cold Chain in Pharma.